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Abstract
Background: Diabetic ketoacidosis or DKA is an acute and fatal disease that is highly prevalent in the
pediatric population. The current gold standard of treatment is continuous intravenous regular insulin (CIRI),
which requires admission to the intensive care unit (ICU) and is a substantial cost to the patient. Alternate
routes of insulin administration, such as subcutaneous (SQ) insulin, do not require ICU admission. If SQ
insulin is found to be safe and efficacious for the treatment of DKA, this treatment modality could replace
continuous IV regular insulin, and therefore decrease the need for ICU admission and cost of stay.
Methods: An exhaustive search of available medical literature was performed using MEDLINE – Ovid,
MEDLINE - PubMed, Web of Science, Google Scholar, and CINAHL. Keywords included: diabetic
ketoacidosis or DKA, subcutaneous insulin, intravenous insulin, and pediatric. Eligible studies were assessed
using the GRADE criteria.
Results: Two articles met inclusion criteria and were included for this systematic review. One study was a
retrospective chart review and the other a randomized controlled clinical trial. The retrospective chart review
looked at 76 instances of DKA and found that median time to DKA resolution was 10.3 hours using SQ
insulin. The controlled clinical trial randomly assigned 30 patients to receive CIRI and 30 patients to receive
SQ insulin. Patients receiving SQ insulin took up to 6 hours longer to achieve full DKA resolution as
compared to the CIRI group. However, in both studies, patients that were treated with SQ insulin experienced
no increase in adverse outcomes including hypokalemia, hypoglycemia, cerebral edema, or death.
Conclusion: Subcutaneous insulin, regular or fast acting, can be used as a safe and effective treatment of DKA
in pediatric patients. Providers should consider administration of SQ insulin every 4 hours if using regular
insulin and every 2 hours if using fast-acting insulin analogs until DKA resolution.
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Abstract  
Background: Diabetic ketoacidosis or DKA is an acute and fatal disease that is highly prevalent 
in the pediatric population.  The current gold standard of treatment is continuous intravenous 
regular insulin (CIRI), which requires admission to the intensive care unit (ICU) and is a 
substantial cost to the patient. Alternate routes of insulin administration, such as subcutaneous 
(SQ) insulin, do not require ICU admission. If SQ insulin is found to be safe and efficacious for 
the treatment of DKA, this treatment modality could replace continuous IV regular insulin, and 
therefore decrease the need for ICU admission and cost of stay.  
Methods:  An exhaustive search of available medical literature was performed using MEDLINE 
– Ovid, MEDLINE - PubMed, Web of Science, Google Scholar, and CINAHL. Keywords
included: diabetic ketoacidosis or DKA, subcutaneous insulin, intravenous insulin, and pediatric.
Eligible studies were assessed using the GRADE criteria.
Results:  Two articles met inclusion criteria and were included for this systematic review. One 
study was a retrospective chart review and the other a randomized controlled clinical trial. The 
retrospective chart review looked at 76 instances of DKA and found that median time to DKA 
resolution was 10.3 hours using SQ insulin. The controlled clinical trial randomly assigned 30 
patients to receive CIRI and 30 patients to receive SQ insulin. Patients receiving SQ insulin took 
up to 6 hours longer to achieve full DKA resolution as compared to the CIRI group. However, in 
both studies, patients that were treated with SQ insulin experienced no increase in adverse 
outcomes including hypokalemia, hypoglycemia, cerebral edema, or death.  
Conclusion:  Subcutaneous insulin, regular or fast acting, can be used as a safe and effective 
treatment of DKA in pediatric patients. Providers should consider administration of SQ insulin 
every 4 hours if using regular insulin and every 2 hours if using fast-acting insulin analogs until 
DKA resolution.  
Keywords:  Diabetic ketoacidosis, subcutaneous insulin, and pediatric patients 
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Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in 
the Pediatric Population 
BACKGROUND 
Diabetic ketoacidosis (DKA) is an acute and life-threatening complication of diabetes 
mellitus that frequently requires hospitalization in the pediatric and adult population. This 
condition results from a relative and absolute deficiency of circulating insulin, combined with 
increased levels of the counterregulatory hormones including catecholamines, glucagon, and 
growth hormone.1-3 Outcomes of this condition involve severe hyperglycemia, metabolic 
acidosis due to ketone formation, and intracellular dehydration caused by hypertonicity in the 
blood vessels.1  
Criteria for DKA in the pediatric population includes blood glucose > 200 mg/dL, 
bicarbonate < 15 mmol/L, venous pH < 7.3, ketonemia, and ketonuria.4 There are different 
severities of DKA, mild, moderate, and severe, that are based on the degree of acidosis. 1 Mild 
DKA has a venous pH <7.3, moderate DKA has a venous pH < 7.2, and severe DKA has a 
venous pH < 7.1.  DKA can be attributed to several causes including lack of treatment due to 
unknown status of diabetes, missed or incorrect dose of insulin in a known diabetic, illness or 
traumatic event in a diabetic, or non-compliance with diet in a diabetic patient.  
After determining the patient is indeed in DKA based on laboratory criteria, the goals of 
treatment include correction of dehydration, correction of acidosis and ketosis, restoration of 
blood glucose to near normal levels, identification and treatment of the precipitating event, and 
avoidance of the treatment complications that can arise.1 Treatment begins with 1-2 hours of 
fluid resuscitation at a rate of 10 mL/kg/hour with normal saline to try to restore peripheral 
perfusion, and then insulin administration is initiated.5 Options for insulin modalities include 
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continuous intravenous regular insulin (CIRI), subcutaneous (SQ) regular insulin or 
subcutaneous fast-acting insulin. Continuous intravenous infusion of low-dose regular human 
insulin is the current standard of care for DKA as stated by the American Diabetes Association 
(ADA)6,7 and the International Diabetes Federation and the International Society for Pediatric 
and Adolescent diabetes (ISPAD).5,6 Endocrinologists prefer IV insulin to SQ injections to treat 
DKA in order to avoid the delay in onset of action due to slower uptake of insulin in the SQ 
form, and to take advantage of the short half-life of IV insulin. Both of these drug properties of 
IV insulin allow for more flexible and rapid dose adjustment.6 However, IV infusions are 
associated with higher hospitalization costs and resource requirements as compared to SQ 
injections.8 Within most medical centers across the United States, treatment of DKA with CIRI 
involves admission to the ICU due to intensity of treatment, as well as hospital policies that 
prevent the use of CIRI outside of ICU setting.8-10  
With the high cost that comes with CIRI due to required ICU admission and continuous 
monitoring, a systematic review6 has assessed the safety and efficacy of subcutaneous insulin as 
a replacement to CIRI for treatment of DKA in adults. This study was done comparing treatment 
of DKA with SQ Lispro to CIRI. The authors, Vincent and Nobecort, concluded that 
administration of SQ Lispro every 1-2 hours is a feasible alternative to CIRI.  While treatment 
with SQ insulin can be considered for adults, DKA is also a highly prevalent condition in 
children. This review will be addressing if subcutaneous insulin is a safe and efficacious 
treatment of DKA exclusively in the pediatric population.  
METHODS 
An exhaustive search of literature was performed using MEDLINE-Ovid, MEDLINE-
PubMed, Google Scholar, CINAHL, and Web of Science. Keywords included: diabetic 
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ketoacidosis or DKA, subcutaneous insulin, intravenous insulin, and pediatric. Inclusion criteria 
included patients under the age of 18, human studies, and studies in English. Studies were 
excluded if they used an insulin bolus during treatment. Bibliographies of studies and relevant 
articles were searched to find further sources. Relevant studies were assessed for quality using 
the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE).11 
RESULTS  
The initial literature search yielded 12 articles for review. After screening abstracts for 
eligibility, 2 articles were selected that met inclusion criteria. One study12 used a randomized 
controlled clinical trial and the other study13 used a retrospective chart review design. See Tables 
I, II, and III.  
Della Manna et al  
 
 This was a randomized clinically controlled trial12 that compared the efficacy of treating 
DKA with a subcutaneous fast-acting insulin analog, humalog (Lispro), to the standard of 
treatment, continuous regular intravenous insulin (CIRI). This clinical trial took place from June 
2001- June 2003. Sixty patients were randomly selected to receive either SQ Lispro or CIRI for 
treatment of DKA. Thirty patients were selected for each treatment modality. Median age of 
patients in SQ insulin group was 11.3 and median age in CIRI group was 12.1 years. All patients 
met required DKA criteria: venous pH <7.3, blood glucose ≥ 16.6 mmol/L (300 mg/dL), 
bicarbonate < 15 mmol/L, ketonuria greater than “++.” After a standard 1-2 hours of fluid 
resuscitation, insulin was started at a dosage of 0.15 units/kg every 2 hours in the SQ Lispro 
group, and 0.1 unit/kg/hour in the CIRI group. At a blood sugar of 13.8 mmol/L (250 mg/dL), 
administration of SQ Lispro was extended to 0.15 units/kg every 4 hours and patients in the CIRI 
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group were taken off IV insulin and transferred to SQ regular insulin at a dose of 0.15 units/kg 
every 4 hours.12 
 Outcomes considered in the study were the rate at which blood glucose declined, the time 
taken for patient’s DKA to resolve, volume of IV fluids, amount of insulin administered, number 
of hypoglycemic events, number of events of cerebral edema, and number of deaths. Serum 
potassium was reported 24 hours following the blood glucose reaching 250 mg/dL in each group. 
Criteria for DKA resolution included the patient having the ability to eat and be mentally alert, a 
venous pH >7.3, bicarbonate >15 mmol/L, and anion gap < 16 mmol/L.12 
 The mean decrease in capillary glucose for the SQ Lispro group and CIRI group was 2.9 
mmol/L/hour and 2.6 mmol/L/hour, respectively. The total time taken for blood glucose to 
decrease to 13.8 mmol/L, or 250 mg/dL, was around 6 hours in both the SQ and CIRI groups. 
Following this, the CIRI group had full DKA resolution within 6 hours, while the SQ group had 
full DKA resolution within 12 hours. The total amount of IV fluid replacement in the SQ group 
was 44 +/- 17.9 mL/kg for a mean period of 4.4 +/- 2.3 hours and in the CIRI group the amount 
of IV fluid administered was 42.7 +/- 17.4 mL/kg for a period of 4.5 +/- 2.2 hours. Amount of 
insulin required to resolve DKA in the SQ Lispro group was 0.28 +/- 0.19 units/kg, whereas in 
the CIRI group insulin required was 0.37 +/- 0.24 units/kg. Number of hypoglycemic events was 
six in the CIRI group and four in the SQ Lispro group. Serum potassium levels 24 hours after 
blood glucose of 250 mg/dL was reached were 3.68 +/- 0.55 in the CIRI group, and 4.05 +/- 0.44 
in the SQ group.  There were no events of cerebral edema or death in this trial. There was no 
required escalation of care in SQ group, which was measured by need to move patients to the 
ICU, or need to switch from SQ Lispro to CIRI.12 
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 Limitations of this study include the inability to blind providers to which treatment is 
being administered. This study did not report the differences between the SQ and CIRI group in 
frequency and severity of hypokalemic events during DKA treatment. Also, in this study an 
unaccounted for variable was introduced which was the administration of bicarbonate to patients 
who has bicarbonate levels < 5.0 mmol/L.12 
Cohen et al 
 
 Through retrospective chart analysis from the years 2007 – 2010, this study 13 evaluated 
the safety and efficacy of subcutaneous (SQ) regular insulin for the treatment of diabetic 
ketoacidosis in children. Average age of patients was 11.6 (+/- 4.0 years). The study included 76 
episodes of DKA, all of which were treated with scheduled doses of SQ regular insulin. After the 
standard 1-2 hours of fluid resuscitation, SQ insulin was administered every 4 hours at a dose of 
0.8 units/kg/day. This dose was adjusted on a sliding scale based on patient’s blood glucose at 
the time of insulin administration. All patients met required DKA criteria: venous pH < 7.3, 
blood glucose > 200 mg/dL, bicarbonate < 15 mmol/L, ketonuria, and ketonemia. Only patients 
with a pH ≥7.0 were treated with subcutaneous insulin.13   
Outcomes considered in this study were the time taken for resolution of DKA, number of 
hypokalemic events, number of hypoglycemic events, number of events of cerebral edema, and 
number of deaths. This study also looked at differences of these outcomes between patients with 
known diabetes versus new onset diabetes and those with mild DKA versus moderate or severe 
DKA. Criteria met for DKA resolution included the patient having the ability to eat and be 
mentally alert, a venous pH >7.3, and bicarbonate >15 mmol/L.13 
Results illustrated DKA resolution in median time of 10.3 hours (Range 5.5 – 14.2 
hours). Hypokalemia was considered at serum potassium levels ≤ 3.5 mEq/L. There were 14 
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hypokalemic events with average serum potassium of 3.1 mEq/L. No ECG abnormalities were 
experienced by any of the patients during hypokalemic events. There was one recorded mild 
hypoglycemic event. No events of cerebral edema or death occurred.  There were no instances in 
which patients required escalation of care, that being, transfers to the ICU, or addition of CIRI 
during treatment of DKA.13  
Limitations included small sample size and a retrospective study design, which doesn’t 
allow for a controlled clinical setting or the insurance of correct timing and dose administration 
of insulin. Also, the study lacked comparison to continuous intravenous regular insulin, the 
standard of treatment of DKA.13 
DISCUSSION 
DKA is the most frequent cause of hospitalization among children and adolescents with 
type I diabetes. The current gold standard of treatment is continuous intravenous regular insulin, 
which requires admission to the ICU and continuous monitoring. CIRI uses an extensive amount 
of hospital resources and results in high admission costs to the patient. The two studies12,13 
included looked at treatment of DKA with subcutaneous insulin, which would limit the need for 
ICU admission in the pediatric population. Both studies looked at time taken for full DKA 
resolution, number of hypoglycemic events, number of events of cerebral edema, number of 
deaths, and number of times escalation of care was required (refer to Table III). Both of the 
studies concluded that full DKA resolution could be obtained with SQ insulin administration 
effectively with no increase in incidences of hypokalemia, hypoglycemia, cerebral edema, or 
death.  
For the Della Manna et al study,12 when comparing the CIRI group to SQ Lispro group, 
DKA resolution was not reached for up to 6 hours longer in the SQ Lispro group. However, this 
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may be attributed to the fact that SQ Lispro administration was extended to every 4 hours after a 
blood glucose of 250 mg/dL was reached. Thereafter, a slower rate of decline in blood glucose 
was observed. Based on the duration of action of SQ Lispro, the researchers from this study state 
continuing SQ Lispro injections at a lower dose every 2 hours may have quickened DKA 
resolution.12 The Cohen et al study13 recorded an average time of 10.3 hours for resolution of 
DKA with the use of SQ regular insulin, which was comparable to times found in the Vincent 
and Nobecourt review.6 This review,6 which looked at studies that compared SQ insulin Lispro 
to CIRI for the treatment of DKA in the adult population, found that there was “no statistically 
significant or clinically relevant differences in the speed of blood glucose decline or the 
resolution of DKA symptoms between the SQ insulin and CIRI groups.”6 Based on the two 
studies included in this review,12,13 this carries down to the pediatric population.  
Two different types of insulin were administered for each study, which poses an 
inconsistency between the studies. The Della Manna et al study12 used subcutaneous Lispro, a 
fast-acting insulin analog, and the Cohen et al study13 used subcutaneous regular insulin. The 
difference between the two types of insulin is the onset of action, which is around 1-20 minutes 
in SQ Lispro, and 1 hour in SQ regular insulin, and the duration of action, which is 3-4 hours for 
SQ Lispro and 4-6 hours for SQ regular insulin.14,15 Based on these properties, administration of 
SQ Lispro was initiated at the frequency of every 2 hours in the Della Manna et al study,12 and 
administration of SQ regular insulin was every 4 hours in the Cohen et al study.13 The same 
outcome of safe and effective DKA resolution was illustrated with both types of SQ insulin.  
 Limitations of the Cohen et al study13 include having relatively small sample size for an 
observational study. Also, specifically with this retrospective chart review study,13 only patients 
who had a pH of ≥ 7.0 were treated with SQ insulin, if the pH was lower than this they were 
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treated with CIRI. This did not allow for assessment of efficacy and safety of SQ regular insulin 
in the truly severe cases of DKA. In regards to Della Manna et al study,12 the providers were not 
blinded to allocation of treatment; however, due to differing methods of treatment of each group, 
intravenous in the ICU vs SQ injections not in the ICU, provider blinding seems difficult. 
Although, the study lacked blinding, all data was objective laboratory results and the need for 
provider blinding was extraneous. CIRI and SQ groups had comparable demographics and 
starting laboratory values for this study.12  
 The use of subcutaneous insulin for the treatment of DKA could reserve the hospital 
resources that are used to treat DKA with CIRI and lower cost of admission for the patient. In a 
study that looked at difference of cost when treating DKA with CIRI in the ICU, as compared to 
SQ insulin on the non-ICU floor, the ICU was associated with 39% higher hospitalization 
charges, which was an average difference of about $5,600 per case.10 A pediatric emergency 
department in Brazil follows identical protocol as the United States for fluid and electrolyte 
administration, as well as laboratory monitoring in DKA patient, but has been treating pediatric 
patients with SQ Lispro since 1996 due to limitations of resources, and reports no incidences of 
cerebral edema or deaths.16 If subcutaneous insulin is just as safe and effective, and poses no 
increased risks for the patient, this method should be a strong consideration for treatment of 
DKA in the pediatric population. 
CONCLUSION 
Subcutaneous insulin should be considered for the treatment of DKA in pediatric 
populations. It has been demonstrated safe and effective at resolving this condition. In seems 
advantageous to the patient, and to hospital resources, to look at alternate treatment options to 
replace continuous intravenous regular insulin for the treatment of DKA. ICU beds and staff 
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should be saved only for those medical conditions that cannot be treated safety outside this 
environment. In order to achieve this, future studies need to be done that focus on comparing 
different types of subcutaneous insulin to find which option provides the safest and most 
effective manor in which to treat DKA.   
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Table I: Quality Assessment of Reviewed Article with GRADE 
Study Design 
Downgrade Criteria Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
Della Manna et al 12 RCT  Not Serious a Not Serious Not Serious Not Serious Unlikely  
 
None  High 
Cohen et al 13 Retrospective   Not Serious Not Serious Not Serious Seriousb Unlikely 
 
None  Very Low  
a Lack of blinding, no downgrade applied due to objectivity of outcomes  
b Small sample size 
 
Table II: Summary of Characteristics of the Reviewed Studies 
Study Study Design  Number 
of patients  
Median Age Type of Insulin  Dose of Insulin  
Della 
Manna et 
al 12 
Controlled 
Clinical Trial – 
randomized  
N = 60  
30: IV 
insulin  
30: SQ 
lispro  
Lispro: 11.3 +/- 
3.6  
 
IV Insulin: 12.1 
+/- 3.3 
Subcutaneous Lispro (fast-acting insulin 
analog) compared to continuous 
intravenous regular insulin  
SQ Lispro – 0.15 units/kg injected q2h until BG is 13.8 mmol/L then 0.15 units/kg 
injected q4h 
 
CIRI – 0.1 units/kg/hour until BG is 13.8 mmol/L then 0.15 units/kg of regular insulin 
injected q4h 
Cohen M 
et al 13 
Retrospective 
chart review  
76 DKA 
episodes 
11.6 +/- 4.0  Subcutaneous Regular Insulin  0.8 units/kg/day – this amount is divided by 6 for q4hour dosing then a sliding scale was 
used based on blood glucose level prior to insulin injection  
  
Table III: Summary of Findings 
Study Outcomes measured to 
show DKA resolution  
Blood Glucose 
Decline  
Time to DKA resolution Number of patients 
requiring escalation of 
care: ICU bed or switch 
from SQ to CIRI  
Average 
Potassium Levels  
Hypoglycemic events  Number of deaths/cerebral 
edema events  
Della 
Manna et 
al 12 
1. Blood Glucose <13.8 
mmol/L 
 
2. pH >7.3  
 
3. Bicarbonate >15 
mmol/L 
IV Insulin: -2.9 
mmol/L/hour 
 
SQ Lispro: -2.6 
mmol/L/hour  
IV Insulin: < 6 hours after  
BG < 13.8 mmol/L (250 mg/dL)  
 
SQ Lispro: < 12 hours after 
BG < 13.8 mmol/L (250 
mg/dL)  
0 IV Insulin – 3.68 
mEq/L (+/- 0.55)  
 
SQ Insulin – 4.05  
mEq/L (+/- 0.44)  
IV Insulin – 6  
SQ Insulin – 4   
0  
Cohen M 
et al 13 
1. Ability to eat  
 
2. Venous pH > 7.3  
 
3. Bicarbonate >15 
mmol/L  
Not recorded  Average of 10.3 hours (5.5 
to 14.2 hours)  
0  14 patients 
experienced 
hypokalemia – 
average K+ during 
hypokalemia 3.1 
mEq/L  
1  0  
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